Inhibition of Complement C1s By Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Efficacy and Safety Results from the Randomized, Placebo-Controlled Phase 3 CADENZA Study

Authors
Category Primary study
ConferenceBlood
Year 2021
This article has no abstract
Epistemonikos ID: 4175417ae6fd0b0f2c743fea21106830756fc576
First added on: Feb 13, 2025